International BioChemical Industries Inc has signed a master distribution agreement with its joint partner Nova BioGenetics Inc. IBCI has entered into this agreement to strengthen its capability for marketing of its products.IBCI will continue to provide R&D technical support to Nova as well as production of products, while maintaining a stronger profit margin due to reduction in overhead.
The company believes this approach will strengthen sales into the market and develop a stronger pipeline.Under this agreement Nova will undertake all sales efforts for IBCI products, technical sales support and marketing programs.Nova has demonstrated they're capable of bringing strong distribution connections to the technology and the ability to move forward on sales agreements.Nova's financial commitment to marketing IBCI's products will give IBCI the required strength to move the products forward with the appropriate marketing and staff.
International BioChemical Industries is emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products.The company's antimicrobial technology is an alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria on contact and can remain active for extended time periods.To date IBCI has received four U.S. patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms.The company has developed several alliances in different industries, such as healthcare, textiles and storm water.